Abstract Details

Title Optic Nerve Pathology and Visual Functioning in Pediatric Patients with anti-MOG Antibodies

Topic Autoimmune Neurology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 1-001

Objective The objective of this study was to analyze the unique optical coherence tomography findings, visual acuity patterns and outcomes of optic neuritis among pediatric patients with anti-MOG antibody associated syndromes.

Background Anti-MOG antibodies have been associated with ADEM, optic neuritis and transverse myelitis in pediatric patients. Some patients have single inflammatory events of the CNS, while others with persistently circulating antibodies have a risk of relapse. In the setting of recurrent episodes patients have been misdiagnosed as multiple sclerosis or neuromyelitis optica. The PERCEPTION Study Group is a 4 center collaboration gathering data about vision outcomes and optical coherence tomography patterns in pediatric patients with various causes of optic neuritis. The shared database included over 40 patients with OCT data, visual acuity data and documented positive anti-MOG antibodies.

Design/Methods Data from anti-MOG antibody positive patients, including visual acuity, RNFL, GCL and history of ON were abstracted from the PERCEPTION database. Data including age and gender were abstracted as was clinical history (age of onset, initial symptoms, history of clinical ON). Age and gender matched patients with RRMS were also analyzed. Impact of RNFL and GCL thinning on visual acuity was quantified. Differences between pediatric anti-MOG antibody and RRMS patients were quantified relative to visual acuity loss, per micron of thinning (as measured by OCT).

Results Pediatric patients with anti-MOG antibody mediated optic nerve damage have relatively preserved visual acuity. In a subset of patients from one center, for example, despite an average RNFL below 50 microns, the MOG-Ab positive patients were able to read 15 letters on the 2.5% low contrast visual acuity chart (25^thpercentile -7.5, 75^thpercentile – 19.25). Data from all centers will be presented.

Conclusions Preliminary results suggest relatively preserved visual acuity despite similar OCT measured patterns of RNFL damage, in pediatric anti-MOG antibody positive patients as compared to pediatric MS patients.

Authors/Disclosures
Benjamin M. Greenberg, MD, FAAN (UT Southwestern Medical Center) PRESENTER	Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Sanofi/Genzyme. Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech/Roche. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sandoz. Dr. Greenberg has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Clene. Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Greenberg has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Siegel Rare Neuroimmune Association. Dr. Greenberg has or had stock in GenrAb.Dr. Greenberg has or had stock in Clene.Dr. Greenberg has received intellectual property interests from a discovery or technology relating to health care. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Leslie A. Benson, MD (Children's Hospital Boston)	The institution of Dr. Benson has received research support from ROHHAD Fight, Inc. The institution of Dr. Benson has received research support from NIH. The institution of Dr. Benson has received research support from Roche/Genentech. Dr. Benson has received personal compensation in the range of $0-$499 for serving as a consultant with MA Department of public health. Dr. Benson has received personal compensation in the range of $10,000-$49,999 for serving as a consultant with National vaccine injury compensation program.
Jennifer Graves, MD, PhD (UCSD)	Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Graves has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Graves has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MSJ. The institution of Dr. Graves has received research support from Octave. The institution of Dr. Graves has received research support from Sanofi. The institution of Dr. Graves has received research support from EMD Serono.
Darrel Conger (UT Southwestern Medical Center)	No disclosure on file
Amy T. Waldman, MD (Children's Hospital of Philadelphia)	Dr. Waldman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SwanBio. An immediate family member of Dr. Waldman has or had stock in Pfizer. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Roche/Genentech. The institution of Dr. Waldman has received research support from Ionis Pharmaceuticals. The institution of Dr. Waldman has received research support from Calico. Dr. Waldman has received publishing royalties from a publication relating to health care. Dr. Waldman has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��